BPA for iclusig
Ended Awarded Last action
- Contract number
- 36E79724A0036
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI ENNFDLWFC6L1
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $123,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement, awarded on October 4, 2024, to Takeda Pharmaceuticals America, Inc., establishes a single-award indefinite delivery vehicle valued at $123.5 million for the procurement of ICLUSIG (ponatinib), a specialized oncology pharmaceutical product. The contract is administered by the National Acquisition Center, a civilian federal agency, and will remain in effect through September 17, 2025. As a child contract under the parent General Services Administration Schedule for Pharmaceuticals and Drugs (FSS-61-IB), this BPA leverages existing GSA schedule pricing and terms to streamline the acquisition process. The agreement was issued to replace and cancel the predecessor BPA 36E79724A0036 in its entirety, consolidating the government's procurement strategy for this critical medication under a single vehicle.
ICLUSIG is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia, making it essential for VA medical facilities and Veterans Integrated Service Networks requiring oncology support. This BPA enables the Department of Veterans Affairs to place delivery orders for multiple dosage strengths—including 10 milligram, 15 milligram, 30 milligram, and 45 milligram tablets—without the delays associated with competitive procurement. As Takeda Pharmaceuticals America, Inc. is a large, foreign-owned pharmaceutical manufacturer with established capabilities in federal healthcare supply, the absence of small business set-asides reflects the specialized nature of the product and the vendor's unique qualifications. The indefinite delivery vehicle structure allows VA medical facilities to efficiently fulfill patient treatment requirements while maintaining budget certainty within the established ceiling value.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0036?
36E79724A0036 was awarded to Takeda Pharmaceuticals America, Inc. by National Acquisition Center (Headquarters) on October 4, 2024.
How much is contract 36E79724A0036 worth?
36E79724A0036's own ceiling is $123,500,000.
Who can order from contract 36E79724A0036?
36E79724A0036 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0036 under another contract?
Yes. 36E79724A0036 is a blanket purchase agreement under 36F79718D0586, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0036 competed?
The extent of competition for 36E79724A0036 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV